

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* LAURENCIN CATO T (Last) (First) (Middle) CONNAUGHT HOUSE 1 BURLINGTON ROAD (Street) DUBLIN 4 Ireland (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol Alkermes plc. [ALKS]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 12/08/2023	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person
Rule 10b5-1(c) Transaction Indication <input type="checkbox"/> Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Ordinary Shares	12/08/2023		M		4,163	A	(1)	16,169	D	
Ordinary Shares	12/08/2023		F		1,000	D	\$25.86	15,169	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					
Non Qualified Stock Option (Right to Buy) ⁽²⁾	\$22.52	11/17/2023		J	V	112		(3)	12/08/2031	Ordinary Shares 112	\$22.52	5,712	D	
Non Qualified Stock Option (Right to Buy) ⁽²⁾	\$22.52	11/17/2023		J	V	422		(4)	12/08/2031	Ordinary Shares 422	\$22.52	21,523	D	
Non Qualified Stock Option (Right to Buy) ⁽²⁾	\$30.863	11/17/2023		J	V	231		(5)	07/07/2032	Ordinary Shares 231	\$30.863	11,785	D	
Non Qualified Stock Option (Right to Buy) ⁽²⁾	\$30.716	11/17/2023		J	V	254		(6)	06/29/2024 06/29/2033	Ordinary Shares 254	\$30.716	12,986	D	
Restricted Stock Unit Award ⁽²⁾	(1)	11/17/2023		J	V	119		(7)	06/29/2024 (7)	Ordinary Shares 119	(1)	6,104	D	
Restricted Stock Unit Award ⁽²⁾	(1)	11/17/2023		J	V	163		(8)	(8)	Ordinary Shares 163	(1)	8,326	D	
Restricted Stock Unit Award	(1)	12/08/2023		M			4,163	(8)	(8)	Ordinary Shares 4,163	(1)	4,163	D	

Explanation of Responses:

- Each restricted stock unit represents a contingent right to receive one ordinary share.
- Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.
- This award is fully vested in accordance with its terms.

4. Shares subject to the stock option award vest in three equal annual installments commencing on 12/8/2022.
5. These options are fully vested in accordance with their terms.
6. Shares subject to the stock option award vest and become exercisable in full on 6/29/2024.
7. Shares subject to the restricted stock unit award vest in full on 6/29/2024.
8. Shares subject to the restricted stock unit award vest in three annual installments commencing on 12/8/2022.

/s/ Shantale Greenson, attorney-
in-fact for Cato T. Laurencin 12/12/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.